Contineum Therapeutics (CTNM) stock

Oral therapies , market cap $346M

Oral therapies for neurological conditions

Worth $346M

$10.56

+2.52%

As of Tuesday's close · Live for Pro members at the open

Quality Score

-4

Poor

In its industry

#203of 281

Biotech

Checks firing

5of 14

Trending down

From 52-week high

-40.6%

under its best in a year

CTNM's Quality Score was unchanged on Tue, Nov 10, at -4.

Follow CTNM's trial news. Pro members can get an alert when Contineum Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CTNM files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is CTNM up?

Up 20% from Nov 5 to Nov 10.

Contineum Therapeutics rose 20% from Nov 5 to Nov 10 while biotech stocks rose a median 5%: it beat its group by 15 points.

Sources: Price history, Nov 10, 2026

The other side, the timeline, and its peers, for Pro members.

Key facts on CTNM

Key facts on CTNM
Holding it back	36.5% more shares than a year ago from Massive's market data
Latest filing	8-K, Nov 3 Reported its quarterly results

1 more reason behind CTNM's -4, free with an account →3 more reasons behind CTNM's -4, for Pro members.

What's next

Thu Nov 12: Stifel Healthcare Conference 2026Investor conference · date confirmed.

CTNM catalysts

Coming up

After its last 4 reports it closed +0.9% on average, higher 3 of 4 times.

What's next for CTNM, and how long its cash lasts

Its trials

A trial underway: Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisPhase 2 · Recruiting · 324 people · main data estimated May 2028 · NCT07284459

For Pro members: 28 filings.

Cash runway

The company says its cash lasts through mid-2029 (8-K, Nov 3).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed May 14, 2025)
At-the-market share sales program (424B5, filed Mar 5, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CEO Carmine N. Stengone sold 2,500 shares on Sep 8, under a planned sale. 19 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Carmine Stengone buys or sells

For Pro members: every trade, and Carmine Stengone’s 13 filings and quotes.

Get an alert when CTNM files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why CTNM scores -4

Poorfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

+5Chart checks 5 of 14 firing right now, one point each
−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on CTNM and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when CTNM's Quality Score turns up

A free account. No card.

How CTNM ranks in Biotech

CTNM is #203 of 281 by Quality Score.

How CTNM ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	CRLCharles River Laboratories International		Open for its score
	CRSPCRISPR Therapeutics		Open for its score
	CTYCity Therapeutics		Open for its score
	DBVTDBV		Open for its score
203	CTNMContineum Therapeutics	5/14	-4

When does CTNM report earnings, and what happens after?

Expected to report Thu Mar 4, after the close (in 114 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CTNM reported on Nov 3, 2026

The quarter

A loss of $0.49 a share, from $0.45.

“This increase was primarily driven by higher expenses related to the PIPE-791 IPF program and employee-related costs.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

CTNM's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase was primarily driven by higher stock-based compensation and employee-related costs.”

From its results filing (SEC filing · Nov 3)

The numbers

Market value: $346M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CTNM: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+0.5%+3.8%-1.6%+1.0%

Mar 5May 5Jul 30Nov 3

Reported	When	Gap	Reaction	5 days
Nov 3, 2026After close	After close	+3.2%	+1.0%	+9.0%
Jul 30, 2026After close	After close	0.0%	-1.6%	-2.5%
May 5, 2026After close	After close	+0.7%	+3.8%	-5.1%
Mar 5, 2026After close	After close	+6.5%	+0.5%	+0.4%

CTNM closed higher after 3 of its last 4 reports.

CTNM has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on CTNM, and all 14 on every stock.Get in free →

CTNM RSI today: 54.3, below its 50-day and 200-day averages

Not scored

RSI 54.3, MACD above signal, below both averages. Not scored.13 readings

The deep dive on CTNM

What it does and how it makes money2 findings"We received an upfront payment of $50.0 million, and we are eligible to receive milestone payments up to an aggregate of approximately $1.0 billion and tiered royalties in the low-double digit to high-teen percent range on future net sales of products containing PIPE-307." (10-K for fiscal 2024)SEC filing · Mar 6, 2025
Where it stands2 findingsFor Pro members2 findings on where CTNM stands: its cash, debt, and share count, for Pro members
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades CTNM, for Pro members

5 more findings on CTNM, each with its source, for Pro members.

CTNM share count over time

37% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of CTNM outstanding, as filed
Shares outstanding	As of
23.1M	Oct 27, 2025
28M	Jul 31, 2025
25.9M	May 9, 2025
25.9M	Feb 28, 2025

Offerings, shelves, and splits of CTNM, from its filings
From its filings	Filed
Set up an at-the-market program for up to $100M of shares, about 29% of its market value	Mar 5, 2026
Raised $90M in a sale of shares, about 26% of its market value	Dec 12, 2025
Registered shares for a later sale (S-3)	May 14, 2025
Raised $110M in a sale of shares, about 32% of its market value	Apr 8, 2024

CTNM's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Carmine N. StengoneCEO and President · 7 trades
Daniel S. LorrainChief Scientific Officer · 15 trades
Tim WatkinsCMO & Head of Development · 4 trades

See insider trades by person

Which ETFs hold CTNM?

In ETFs: CTNM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Contineum Therapeutics

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

51 employeesSan Diego, CAcontineum-tx.com

What Contineum Therapeutics says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property.”

From its annual report, SEC filing · Mar 6, 2025

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on CTNM and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn CTNM's score around: 8 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

See CTNM's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: CTNM's Quality Score is -4 (Poor), #203 of 281 in Biotech.

What does CTNM's Quality Score say?

CTNM scores -4 today, which Breakaway calls Poor. It is #203 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Up 20% from Nov 5 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CTNM's Quality Score?

CTNM scores -4 today, which Breakaway calls Poor (below zero). That is #203 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CTNM's -4.

When does CTNM report earnings?

Expected to report Thu Mar 4, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. CTNM closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.